Acute kidney injury (AKI) may progress to chronic kidney disease, and there is an urgent need for approaches that improve the limited regeneration of the renal tubules after AKI.

Hong Kong-based Insilico Medicine has announced positive results from two Phase I studies of ISM5411 (NCT06012578), a novel gut-restricted and prolyl hydroxylase domain (PHD)-specific inhibitor ...